The company received the designation for its atrioventricular interval modulation therapy, a novel pacemaker-based treatment aimed at reducing blood pressure in patients with uncontrolled hypertension and elevated cardiovascular risk.
The newly cleared system uses advanced identification and antimicrobial susceptibility testing algorithms to support the interpretation of complex microbiological data.